Journal
Cancer Research Communications
Publication Date
8-15-2023
Volume
3
Issue
8
First Page
1551
Last Page
1563
Document Type
Open Access Publication
DOI
10.1158/2767-9764.CRC-22-0501
Rights and Permissions
Wang J, Saltzman AB, Jaehnig EJ, Lei JT, Malovannaya A, Holt MV, Young MN, Rimawi MF, Ademuyiwa FO, Anurag M, Kim BJ, Ellis MJ. Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 Aug 15;3(8):1551-1563. doi: 10.1158/2767-9764.CRC-22-0501. © 2023 The Authors; Published by the American Association for Cancer Research This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
Recommended Citation
Wang, Junkai; Saltzman, Alexander B; Jaehnig, Eric J; Lei, Jonathan T; Malovannaya, Anna; Holt, Matthew V; Young, Meggie N; Rimawi, Mothaffar F; Ademuyiwa, Foluso O; Anurag, Meenakshi; Kim, Beom-Jun; and Ellis, Matthew J, "Kinase inhibitor pulldown assay identifies a chemotherapy response signature in triple-negative breast cancer based on purine-binding proteins." Cancer Research Communications. 3, 8. 1551 - 1563. (2023).
https://digitalcommons.wustl.edu/oa_4/3121
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
